Figure 7.

Characterization of murine tumor model used and the immune landscape change upon iFSP1 treatment. (A‒C) In vivo HCC tumors were induced via HDTVi of plasmids carrying Keap1^KO/c-Myc^OE (or Apc^KO/c-Myc^OE) in C57BL/6N mice fed with HFD. (A) Representative hematoxylin and eosin staining of Keap1^KO/c-Myc^OE HCC tumor. (B) Representative staining of FSP1 expression from Apc^KO/c-Myc^OE or Keap1^KO/c-Myc^OE HCC tumors at protein level by IHC staining. (C) RT-qPCR demonstrated the upregulation of Afp in tumorous (T) tissues when compared with NT liver tissues in Keap1^KO/c-Myc^OE HCC tumor. (D) Administration of iFSP1 altered myeloid cells infiltration, including neutrophils (CD11b⁺ Ly6G⁺), monocytes (CD11b⁺ Ly6C⁺), M1 macrophages (CD11b⁺ F4/80⁺ CD86⁺ MHCII⁺), and M2 macrophages (CD11b⁺ F4/80⁺ CD206⁺) in HDTVi-induced HCC tumors. (E) Administration of iFSP1 increased number of T cells (CD3⁺) and T effector cells (CD44⁺ CD62L^-) in HDTVi-induced HCC tumors. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001 vs NT or vehicle as indicated. Student t test. A‒B: 20× magnification, scale bar = 100 μm.